According to Zacks, “IsoPlexis Corporation is a life science technology company that designs solutions for the development of curative drugs and personalized therapies. IsoPlexis Corporation is based in BRANFORD, Conn. “
Several other research companies also commented on the ISO. Morgan Stanley lowered its price target on IsoPlexis shares from $17.00 to $12.00 and set an “overweight” rating on the stock in a Tuesday, February 15 report. SVB Leerink reduced its price target on IsoPlexis shares from $20.00 to $15.00 and set an “outperform” rating on the stock in a Thursday, January 27 report. One analyst rated the stock with a hold rating and four have issued a buy rating for the company’s stock. According to data from MarketBeat, IsoPlexis currently has an average rating of “Buy” and a consensus price target of $13.31.
IsoPlexis stock traded down $0.12 in Friday’s midday session, hitting $1.99. The company’s stock had a trading volume of 67,686 shares, compared to an average volume of 89,382. IsoPlexis has a 1-year low of $1.62 and a 1-year high of $16.95. The company has a debt ratio of 0.34, a current ratio of 7.78 and a quick ratio of 5.85. The company has a 50-day moving average price of $2.59 and a two-hundred-day moving average price of $6.01.
IsoPlexis (NASDAQ: ISO – Get a rating) last reported results on Wednesday, May 11. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Analysts expect IsoPlexis to post -1.97 EPS for the current year.
Several institutional investors have recently changed their positions in the stock. Citigroup Inc. purchased a new equity stake in IsoPlexis during Q4 valued at approximately $36,000. California State Teachers Retirement System purchased a new stake in IsoPlexis during Q4 for a value of approximately $43,000. Deutsche Bank AG acquired a new stake in IsoPlexis during Q4 worth approximately $47,000. Wells Fargo & Company MN acquired a new stake in IsoPlexis during Q4 valued at approximately $48,000. Finally, JPMorgan Chase & Co. acquired a new stake in IsoPlexis during the 4th quarter at a value of approximately $51,000. 76.49% of the shares are currently held by institutional investors.
About IsoPlexis (Get a rating)
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative drugs and personalized therapies in the United States, Canada, United Kingdom, Belgium, France, Czech Republic, Spain, in Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia and Korea.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for IsoPlexis Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for IsoPlexis and related companies with MarketBeat.com’s FREE daily email newsletter.